Evommune (NYSE:EVMN) Insider Sells $33,480.00 in Stock

Evommune, Inc. (NYSE:EVMN) insider Jeegar Pravinkumar Patel sold 1,488 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.50, for a total transaction of $33,480.00. Following the sale, the insider directly owned 46,403 shares in the company, valued at approximately $1,044,067.50. The trade was a 3.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jeegar Pravinkumar Patel also recently made the following trade(s):

• On Monday, June 1st, Jeegar Pravinkumar Patel sold 16,687 shares of Evommune stock. The stock was sold at an average price of $22.74, for a total transaction of $379,462.38.

Evommune Price Performance

Shares of Evommune stock traded down $0.72 during trading hours on Wednesday, hitting $23.53. The company had a trading volume of 1,043,288 shares, compared to its average volume of 453,427. The company’s 50-day moving average is $23.14 and its two-hundred day moving average is $22.27. The company has a market cap of $847.59 million and a P/E ratio of -2.48. Evommune, Inc. has a twelve month low of $13.89 and a twelve month high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. Sell-side analysts expect that Evommune, Inc. will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Evommune

A number of institutional investors and hedge funds have recently made changes to their positions in EVMN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Evommune during the fourth quarter worth about $34,000. Strs Ohio acquired a new position in Evommune in the 1st quarter valued at about $41,000. The Manufacturers Life Insurance Company acquired a new position in Evommune in the 4th quarter valued at about $179,000. XTX Topco Ltd purchased a new stake in Evommune during the 4th quarter valued at approximately $321,000. Finally, Oxford Asset Management LLP purchased a new stake in Evommune during the 4th quarter valued at approximately $335,000.

Wall Street Analysts Forecast Growth

EVMN has been the topic of a number of research analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 target price on shares of Evommune in a research report on Friday, April 10th. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Stifel Nicolaus assumed coverage on Evommune in a research report on Friday, May 1st. They set a “buy” rating and a $54.00 price target on the stock. Clear Str upgraded Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Morgan Stanley increased their price objective on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Evommune currently has an average rating of “Buy” and a consensus target price of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.